Impact of secretome containing extracellular vesicles from human induced pluripotent stem cell-derived cardiomyocytes.
The study reveals dynamic changes in the secretome of hiPSC-CMs during manufacturing, highlighting a transition towards tissue repair signaling by Day 25. These findings could inform the development of more effective hiPSC-CM therapies.
Where it sits
this study against the rest of the sermorelin corpusSummary and findings
The study examined the secretome dynamics of human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) during manufacturing. Multiomics profiling was used to identify changes in the secretome profile from Day 4 to Day 25. The Day 25 secretome showed enhanced mesenchymal stem cell migration and endothelial tube formation.
Abstract
<h4>Introduction</h4>Cell transplantation therapy using human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) has shown promise for ischemic heart disease. Although paracrine effects mediated by the secretome are recognized as key mechanisms underlying the therapeutic effects of hiPSC-CMs, dynamic changes in the secretome profile during the manufacturing of hiPSC-CMs remain poorly understood. This study was aimed at elucidating the secretome dynamics of clinical-grade hiPSC-CMs to identify their "mode of action" (MoA) and "candidate quality attributes."<h4>Methods</h4>We integrated multiomics profiling, including total RNA-sequencing, proteome analysis, and extracellular vesicle (EV)-derived microRNA-sequencing, with functional assays (cell proliferation, cell migration, and endothelial tube formation) to analyze samples obtained at different time points in the hiPSC-CM manufacturing process (Day 4-25).<h4>Results</h4>High-purity hiPSC-CMs (>95% cardiac troponin T-positivity) exhibited distinct transcriptomic maturation between Day 16 and Day 25, characterized by the upregulation of cardiac marker genes. Proteomic clustering revealed four distinct stages, with functional transition from proliferation-centric signaling to tissue-repair signaling. Notably, the purified Day 25 secretome showed a qualitative shift toward a platelet-derived growth factor- and stromal cell-derived factor 1-rich profile. Simultaneously, EVs from the Day 25 secretome were enriched in "myomiRs" (miR-133b, -208b, -499b) and multiple anti-proliferative miRNAs (let-7e-5p, miR-145-5p). Functionally, the Day 25 secretome significantly enhanced mesenchymal stem/stromal cell (MSC) migration and promoted the formation of mature, highly branched endothelial tubes compared with the secretome from earlier stages.<h4>Conclusions</h4>The hiPSC-CM secretome containing EVs undergoes programmed evolution during manufacturing, with functional transition from promotion of undifferentiated growth to complex tissue repair through stable angiogenesis and MSC recruitment. These findings establish a molecular foundation for the MoA of hiPSC-CM therapy and provide critical candidate quality attributes to ensure the potency and consistency of clinical-grade cardiac products.
Background
The study addresses the biological question of how the secretome of hiPSC-CMs evolves during manufacturing and its implications for ischemic heart disease therapy. Previous research has highlighted the therapeutic potential of hiPSC-CMs, particularly through paracrine effects, but the dynamic changes in their secretome profile were not well understood. This research is significant as it aims to elucidate the mode of action and identify quality attributes critical for clinical-grade hiPSC-CM products.
Methods
The study employed multiomics profiling, including total RNA-sequencing, proteome analysis, and extracellular vesicle-derived microRNA-sequencing. Functional assays were conducted to assess cell proliferation, migration, and endothelial tube formation. Samples were analyzed at various time points from Day 4 to Day 25 during the hiPSC-CM manufacturing process.
Results
The primary observation was a distinct maturation of hiPSC-CMs between Day 16 and Day 25, with upregulation of cardiac marker genes. Proteomic analysis identified four stages of functional transition, with the Day 25 secretome showing a shift towards tissue-repair signaling. The Day 25 secretome was enriched in growth factors and miRNAs that enhanced MSC migration and endothelial tube formation compared to earlier stages.
Interpretation
The findings suggest that the secretome of hiPSC-CMs undergoes significant changes during manufacturing, transitioning from promoting undifferentiated growth to facilitating tissue repair. While the study provides a molecular basis for the mode of action of hiPSC-CM therapy, the clinical significance remains uncertain due to the in vitro nature of the findings. Further research is needed to confirm these effects in vivo and assess their therapeutic potential.
Key findings
- >95% cardiac troponin T-positivity in hiPSC-CMs.
- Distinct transcriptomic maturation between Day 16 and Day 25.
- Day 25 secretome enriched in platelet-derived growth factor and stromal cell-derived factor 1.
- EVs from Day 25 secretome enriched in myomiRs and anti-proliferative miRNAs.
- Day 25 secretome significantly enhanced MSC migration and endothelial tube formation.
Limitations
- In vitro study, no in vivo validation.
- Focus on manufacturing process, not direct clinical outcomes.
- Short observation period up to Day 25.
- Potential translational gap to clinical settings.